A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

BACKGROUND: Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1 A guideline recommendation for prevention of CDI, after r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakobs, Florian, Wingen-Heimann, Sebastian Marcel, Jeck, Julia, Kron, Anna, Cornely, Oliver Andreas, Kron, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428130/
https://www.ncbi.nlm.nih.gov/pubmed/34496836
http://dx.doi.org/10.1186/s12913-021-06970-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428130/
https://www.ncbi.nlm.nih.gov/pubmed/34496836
http://dx.doi.org/10.1186/s12913-021-06970-8

Ejemplares similares